Cure8 research brief
The study suggests simple blood-based trace-element ratios (Cu/Zn, Cu/Se) may reflect clinical disease activity in IBD. If validated, they could become an additional, inexpensive biomarker to monitor inflammation alongside existing tests.
Clinicians and researchers interested in IBD biomarkers; adult patients with Crohn’s disease or ulcerative colitis who follow developments in blood tests for disease activity.
This study measured serum copper, zinc, and selenium in people with Crohn’s disease, ulcerative colitis, and non-IBD controls to calculate Cu/Zn and Cu/Se ratios and compare them to clinical disease activity scores (CDAI and partial Mayo) and recent endoscopy.
The authors report that both Cu/Zn and Cu/Se ratios were higher on average in patients with moderate-to-severe IBD activity versus those in remission/mild disease and versus controls; the ratios correlated with CDAI in Crohn’s disease.
The ratios differed by endoscopic healing status overall, but the Cu/Zn difference between healed and unhealed patients was not statistically significant after adjustment.
The paper concludes these trace-element ratios are associated with clinical activity but that their added value beyond established biomarkers (and their reliability for assessing endoscopic healing) is uncertain. The authors call for longitudinal validation before routine clinical use.
This is a cross-sectional study with prospective enrollment and an abstract-level summary provided by the journal. Cross-sectional association does not prove the ratios track change over time or improve on current tests; the authors note longitudinal validation is needed before clinical use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
Biomarkers of gut barrier integrity and oxidative stress could reveal hidden inflammation, help predict disease progression, and indicate likely treatment response—steps toward more personalized IBD care.
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
